About Egetis
Egetis is a company based in Stockholm (Sweden) founded in 2020 by Nicklas Westerholm.. Egetis offers products and services including Emcitate and Aladote. Egetis operates in a competitive market with competitors including NGM Biopharmaceuticals, Nimbus Therapeutics, Mirum Pharmaceuticals, Madrigal Pharmaceuticals and Akero Therapeutics, among others.
- Headquarter Stockholm, Sweden
- Founders Nicklas Westerholm
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Egetis Therapeutics Ab
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
-
Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Egetis
Egetis offers a comprehensive portfolio of products and services, including Emcitate and Aladote. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treats MCT8 deficiency syndrome through targeted therapy.
Manages paracetamol overdosing with effective intervention.
Unlock access to complete
Unlock access to complete
Funding Insights of Egetis
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Egetis
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Egetis
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Egetis Comparisons
Competitors of Egetis
Egetis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, Nimbus Therapeutics, Mirum Pharmaceuticals, Madrigal Pharmaceuticals and Akero Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| domain | founded_year | HQ Location |
Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for metabolic disorders are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics are developed for diseases with impaired kidney function.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Egetis
Frequently Asked Questions about Egetis
When was Egetis founded?
Egetis was founded in 2020.
Where is Egetis located?
Egetis is headquartered in Stockholm, Sweden.
Who is the current CEO of Egetis?
Nicklas Westerholm is the current CEO of Egetis.
What does Egetis do?
Developer of therapeutics for rare and other diseases. The drug candidate includes Aladote to reduce the risk of acute liver injury associated with acetaminophen or paracetamol poisoning, Emcitate for the treatment of MCT8 deficiency a rare inborn error of thyroid hormone signaling, and PledOx to reduce nerve damage associated with chemotherapy.
Who are the top competitors of Egetis?
Egetis's top competitors include Nimbus Therapeutics, NGM Biopharmaceuticals and Madrigal Pharmaceuticals.
What products or services does Egetis offer?
Egetis offers Emcitate and Aladote.